FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

SILVER SPRING, Md., May 23, 2023 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two formulations,…